iBio, Inc.
IBIOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 8, 2026 | Raymond James | $5.00(+175%) | $1.82 | TheFly | |
| Oct 17, 2025 | Leerink Partners | Roanna Ruiz | $2.00(+137%) | $0.85 | TheFly |
| Jul 22, 2024 | Loop Capital Markets | Kemp Dolliver | $3.60(+63%) | $2.21 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | Jul 2, 2026 |
| Chardan Capital | maintain | Buy | Apr 9, 2026 |
| Chardan Capital | maintain | Buy | Mar 18, 2026 |
| Chardan Capital | maintain | Buy | Feb 12, 2026 |
| Chardan Capital | maintain | Buy | Jun 25, 2025 |
| Chardan Capital | maintain | Buy | May 6, 2025 |
| Chardan Capital | maintain | Buy | May 5, 2025 |
| Chardan Capital | maintain | Buy | Jun 3, 2024 |
| Cantor Fitzgerald | downgrade | Overweight →Neutral | Oct 7, 2022 |
| JMP Securities | maintain | Outperform | Nov 29, 2021 |
| Cantor Fitzgerald | maintain | Overweight | Jan 22, 2021 |
| Cantor Fitzgerald | maintain | Overweight | Jan 21, 2021 |
| Alliance Global Partners | maintain | Buy | Jun 26, 2020 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.07| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 28, 2026 | $-0.04 | $-0.07 | — | $80.0K |
| May 12, 2026 | $-0.07 | $-0.06 | — | $20.0K |
| Feb 10, 2026 | $-0.09 | $-0.08 | — | $50.0K |
| Nov 12, 2025 | $-0.11 | $-0.07 | $100.0K | $33.3K |
| Sep 5, 2025 | $-0.31 | $-0.39 | $200.0K | $100.0K |
| May 2, 2025 | $-0.49 | $-0.39 | — | $100.0K |
| Feb 10, 2025 | $-0.48 | $-0.45 | $200.0K | $100.0K |
| Nov 12, 2024 | $-0.46 | $-0.48 | — | — |
News
SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the following investor conferences in November and December 2026.
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human trials of IBIO-610 in first half of 2027 SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, highlighted preclinical body-composition data f…
Squarepoint Ops LLC acquired a new stake in iBio, Inc. (NASDAQ: IBIO) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 498,872 shares of the company's stock, valued at approximately $873,000. Squarepoint Ops LLC owned approximately 0.78% of iBio at the end of the most recent
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston.
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. “Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase …